Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-450 for Maintenance of Remission in CAPS
NCT04524858Phase 2Terminated
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zunsemetinib in cryopyrin-associated periodic syndrome (CAPS), sponsored by Aclaris Therapeutics, Inc.. Started Oct 2020; status: terminated.
02
Drugs
zunsemetinib
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on NCT04524858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524858.